Cheng Andrew's Form 4/A amendment
AmendedAkero Therapeutics, Inc. (AKRO) · filed Mar 2, 2022
- Accession no.
- 0001104659-22-029565
- Filed
- Mar 2, 2022
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jan 11, 2022
This filing lists no transactions. It carries over 3 transactions from the original filing that it did not restate. Open-market sales total $195.5K.
This amendment restates part of 0001104659-22-003317 (filed Jan 11, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cheng AndrewCIK 0001778307 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001104659-22-003317 (filed Jan 11, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 10, 2022 | Common Stock | MOption exerciseAcquired | +10,000 | $0.62 | +$6,200 | 308,996 | Direct | |
| Jan 10, 2021 | Common Stock | SSaleDisposed | −10,000 | $19.55F2 | −$195,500 | 298,996 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 10, 2022 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 320,868 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.225 to $19.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
This amendment has no footnotes.
Remarks
This amendment is being filed to correct Andrew Cheng's aggregate beneficial holdings, which inadvertently excluded 10,000 shares of common stock held by Andrew Cheng prior to the exercise of his options in the reported transaction.